In the early days of the COVID-19 pandemic, Moderna (NASDAQ: MRNA) was a top performer, from both a share-price and an ...

Valued at a market cap of $9.6 billion, Cambridge, Massachusetts-based Moderna, Inc. (MRNA) is a biotechnology company that ...

Furthering its goal to grow the reach of its mRNA vaccines and guard against future pandemics, Moderna cleared a key ...

The first quarter of 2025 was a tough one. The S&P 500 lost 4.6%, and the Nasdaq Composite lost 10.4%. Following the trend, ...

As the 2020 pandemic became a distant memory and millions of Americans returned back to their old lives, some were left ...

Moderna shares may remain under the microscope on Tuesday after sinking to a five-year low following news that the Food and Drug Administration’s top vaccine official has resigned. Watch these key ...

However, in the later stages of the pandemic, demand for the product declined, and Moderna shifted to a loss. For example, last year, the company brought in $3.2 billion in revenue, compared to more ...

Leerink Partners analyst David Risinger maintained a Sell rating on Moderna (MRNA – Research Report) yesterday and set a price target of ...

In this article, we are going to take a look at where Moderna, Inc. (NASDAQ:MRNA) stands against other best long term growth stocks to buy according to billionaires. As per Barclays, the US ...

US mRNA specialist Moderna (Nasdaq: MRNA) has announced that its manufacturing facility in the UK has been granted a manufacturer’s license by the Medicines and Healthcare products Regulatory Agency ...

Concern is growing among public health experts that anti-vaccine sentiments within federal and state governments may derail ...